9605 Medical Center Drive, Suite 270
Rockville, Maryland 20850
August 20, 2018 | ||||
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, NE
Washington, D.C. 20549
Attention: | Ms. Irene Paik |
Ms. Christine Westbrook
Re: | Synthetic Biologics, Inc. |
Registration Statement on Form S-3
Filed August 1, 2018
File No. 333-226500
Dear Mss. Paik and Westbrook:
Synthetic Biologics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 so that it may become effective at5:00 p.m. (New York City Time) onWednesday,August 22, 2018, or as soon thereafter as reasonably practicable.
The Company hereby authorizes its legal counsel, Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours, | ||||
SYNTHETIC BIOLOGICS, INC. | ||||
By: | /s/ Steven A. Shallcross | |||
Name: Title: | Steven A. Shallcross Interim Chief Executive Officer and Chief Financial Officer |